<?xml version="1.0" encoding="UTF-8"?>
<MedicinalProductInteraction xmlns="http://hl7.org/fhir">
  <id value="example"/>
  <meta>
    <security>
      <system value="http://terminology.hl7.org/CodeSystem/v3-ActReason"/>
      <code value="HTEST"/>
      <display value="test health data"/>
    </security>
  </meta>
  <description value="Inhibitors of CYP3A4 and P-gp\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\nequixaban Cmax.\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\nsection 4.4).\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp."/>
  <interactant>
    <itemCodeableConcept>
      <coding>
        <system value="http://ema.europa.eu/example/interactant"/>
        <code value="ketoconazole"/>
      </coding>
    </itemCodeableConcept>
  </interactant>
  <interactant>
    <itemCodeableConcept>
      <coding>
        <system value="http://ema.europa.eu/example/interactant"/>
        <code value="itraconazole"/>
      </coding>
    </itemCodeableConcept>
  </interactant>
  <type>
    <coding>
      <system value="http://ema.europa.eu/example/interactionsType"/>
      <code value="StrongInhibitorofCYP3A4"/>
    </coding>
  </type>
  <effect>
    <coding>
      <system value="http://ema.europa.eu/example/interactionseffect"/>
      <code value="Increasedplasmaconcentrations"/>
    </coding>
  </effect>
  <management>
    <text value="Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp"/>
  </management>
</MedicinalProductInteraction>
